Dear Editor,

We read with great interest the paper of Pappalardo et al. [1]. In this paper, the authors constructed a very nice model predicting the mortality risk while on veno-venous extra-corporeal membrane oxygenation (vvECMO) in patients with acute respiratory distress syndrome (ARDS) due to H1N1 pneumonia. These patients were analyzed retrospectively from a large Italian vvECMO network [2]. Until publication of this paper, inclusion and exclusion criteria for vvECMO treatment were based on expert opinion [3]. The authors constructed the model from the retrospective data of 60 patients, of which 82 % had H1N1 pneumonia with a survival rate of 71 %. The remaining ARDS patients had a survival rate of 52 %. In another validation set containing 74 patients, the authors tested their model: the area under the curve (AUC) of the receiver operating characteristic (ROC) was 0.69 to predict mortality while on ECMO with a ECMOnet score >4.5 points, with a sensitivity of 51 % and a specificity of 76 %.

In our center, we have treated 44 patients with vvECMO: 50 % for bacterial pneumonia, 20 % for viral pneumonia and 27 % for auto-immune pneumonitis disease. The overall survival rate while on vvECMO was 73 %. When applying the ECMOnet score to our patients, the optimal cut-off point (calculated with the Youden index) was an ECMOnet score of 6.5. The AUC with an ECMOnet score >6.5 was exactly 0.69 for predicting mortality while on ECMO with a sensitivity of 50 % and a specificity of 80 % (see Fig. 1). AUC of the oxygenation index and APACHEII was 0.52 and 0.54, respectively.

Fig. 1
figure 1

The number of patients (%) alive and deceased while on veno-venous extracorporeal membrane oxygenation (ECMO) with a ECMOnet score cutoff point of 6.5

Therefore, it seems that the ECMOnet score is a promising scoring system with a fair specificity in predicting mortality while on vvECMO, although with a higher cut-off point. At least, the ECMOnet score is much better than traditional scoring systems such as oxygenation index or APACHEII.